01 6GILEAD
02 25GILEAD SCIENCES INC
03 5MSD MERCK CO
01 110039718*PED
02 17125879
03 17176220
04 17635704
05 18148374
06 38486975
07 58592397
08 18633219
09 38716264
10 18841310
11 18981103
12 39457036
13 39744181
14 19891239
15 110039718
16 110603282
17 110842751
18 110857102
19 17176220*PED
20 17635704*PED
21 18148374*PED
22 18633219*PED
23 18981103*PED
24 19891239*PED
01 8Y
02 28Blank
01 29Y
02 7Blank
01 142024-01-13
02 12025-04-21
03 12025-12-09
04 12026-08-27
05 22026-10-26
06 12027-02-27
07 22027-04-26
08 22029-09-03
09 22030-03-03
10 12030-04-30
11 12030-10-30
12 32031-10-07
13 12032-10-06
14 12033-01-14
15 12033-04-06
16 22036-11-29
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
Patent Expiration Date : 2024-01-13
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8592397
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 202123
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2026-10-26
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 7635704
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2026-10-26
Patent Expiration Date : 2024-01-13
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8592397
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 21752
Patent Use Code : U-248
Delist Requested :
Patent Use Description : TREATMENT OF HIV
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2024-01-13
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8716264
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2025-12-09
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8841310
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 202123
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2025-12-09
Patent Expiration Date : 2024-01-13
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 9457036
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 21752
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2024-01-13
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 9457036
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 202123
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2024-01-13
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 9457036
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2024-01-13
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 9744181
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
LOOKING FOR A SUPPLIER?
